ARPA-H's Advanced Manufacturing Incubator for DNA (AMI-DNA) program is contracting with GE HealthCare’s Flexible Automation for Scalable Health (FLASH) team to develop and deploy a modular, automated cell-free enzymatic DNA manufacturing platform.  

The FLASH system will be a “DNA printer” that uses enzymes instead of traditional chemical synthesis to produce accurate, ready-to-use DNA. Enzymes are proteins that act like tiny machines to perform biological reactions, including building and repairing DNA. By using these enzymes together with automation, the FLASH system will rapidly assemble and purify large, complex DNA genes for discovering and developing new therapies. The FLASH system will also integrate biosecurity and cybersecurity safeguards for safe and secure DNA printing.  

Following development of the FLASH system, it will be distributed to early adopters as part of the AMI-DNA program, enabling researchers developing new DNA-based medicines to produce custom DNA on demand quickly, safely, and at scale. The AMI-DNA and FLASH partnership will catalyze the DNA printing technology needs for the therapies of tomorrow.